NH HB1809

Establishes a medical psilocybin program within the Department of Health and Human Services to allow supervised therapeutic use of psilocybin for patients with treatment-resistant depression, PTSD, and substance use disorders

Requires providers to be both licensed healthcare professionals and approved psilocybin producers, with applications including facility locations, staff qualifications, and prior authorization history from other states

Creates an 11-member medical psilocybin advisory board including researchers, veterans' affairs representatives, addiction specialists, and administrators from existing psilocybin programs in other states

Exempts approved provider/producers from state criminal prosecution for possession, production, or sale of therapeutic psilocybin amounts administered to qualified patients

Program implementation is contingent on advisory board certification within 2 years; estimated costs include $250,000 in the first full year for staff and equipment, decreasing to $224,000-$236,000 in subsequent years